Sustained response to onabotulinumtoxin A in patients with chronic migraine: real-life data

Table 3 Univariate comparison of the characteristics of responders vs non-responders to treatment with onabotulinumtoxin-A

	Non-responders (n = 49)	Anytime responders (n = 66)	P value	Sustained responders (n = 33)	P value
Age, median (IQR)	50 (42–55)	49 (44–54)	0.627	49 (45–53)	0.491
Female sex, n (%)	43 (87.8)	54 (81.8)	0.386	28 (84.8)	0.705
Migraine years, median (IQR)	31 21.5–40)	30 (22–40)	0.913	25 (20–34)	0.155
Chronic migraine duration (months), median (IQR)	65 (25–120)	49 (21–126)	0.732	31 (15.5–60)	0.030
Monthly headache days, median (IQR)	30 (30–30)	30 (24–30)	0.176	25 (21.5–30)	0.013
Medication overuse, n (%)	37 (82.2)	52 (78.8)	0.656	22 (66.7)	0.114
Aura, n (%)	11 (23.4)	8 (12.1)	0.114	3 (9.1)	0.137^a
Allodynia, n (%)	18 (45.0)	20 (33.9)	0.265	13 (41.9)	0.796
Unilateral headache, n (%)	18 (38.3)	30 (45.5)	0.449	15 (45.5)	0.522
Throbbing headache, n (%)	30 (63.8)	44 (66.7)	0.755	21 (63.6)	0.986
Diffuse headache, n (%)	11 (23.4)	13 (20.0)	0.665	5 (15.2)	0.409^a
Frontal headache, n (%)	23 (48.9)	37 (56.1)	0.454	22 (66.7)	0.116
Temporal headache, n (%)	26 (55.3)	33 (50.0)	0.577	17 (51.5)	0.737
Orbital headache, n (%)	13 (27.7)	21 (31.8)	0.635	7 (21.2)	0.612
Occipital headache, n (%)	7 (14.9)	8 (12.1)	0.669	4 (12.1)	0.999^a
Parietal headache, n (%)	9 (19.1)	6 (9.1)	0.120	3 (9.1)	0.341^a
Vertex headache, n (%)	6 (12.8)	3 (4.5)	0.112^a	2 (6.1)	0.459^a
Concurrent oral preventive treatments, n (%)
At baseline	28 (57.1)	33 (50.0)	0.448	17 (51.5)	0.616
Withdrawn during treatment	4 (8.2)	4 (6.1)	0.722^a	4 (12.1)	0.708^a
Changed during treatment	13 (26.5)	13 (19.7)	0.386	7 (21.2)	0.582
Initiated during treatment	2 (4.1)	9 (13.6)	0.113^a	5 (15.2)	0.111^a

ISSN: 1129-2377